Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,126.61
(
-0.17%
)
US TECH 100
26,383.60
(
0.31%
)
Dow Jones
48,756.44
(
-0.78%
)
Brent Oil
110.49
(
5.82%
)
Bitcoin
75,957.78
(
-0.51%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: thealias2002 post# 171370

Monday, 01/26/2015 2:05:18 PM

Monday, January 26, 2015 2:05:18 PM

Post# of 347009

Are his research rights 'owned' by a biotech or pharma ala Thorpe/PPHM/UTSW?

Curious



I'd be curious as well, because why would Troy Luster try to go around PS Targeting when he just may know that the work of Dr. Thorpe in PS Targeting is all prepped and ready to go for vaccines. Troy still shows at Dana Farber and if we know Beta Bodies patent is moving forward then Troy knows of it and maybe he does have some insight for Beta Bodies in vaccines

https://www.dana-farber.org/contact-us/staff-directory.aspx?spage=1&stext=luster

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote